New pill aims to shrink Hard-to-Treat cancers
NCT ID NCT06258408
First seen Nov 17, 2025 · Last updated May 24, 2026 · Updated 27 times
Summary
This early-stage study tests an experimental pill called BB102 in people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (FGFR4) that some cancers need to grow. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 78 participants will take the pill by mouth, and researchers will monitor side effects and measure drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
Contact Email: •••••@•••••
-
Nanfang Hospital
RECRUITINGGuangzhou, Guangdong, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.